M
Mario Hermsen
Researcher at International Sleep Products Association
Publications - 110
Citations - 2950
Mario Hermsen is an academic researcher from International Sleep Products Association. The author has contributed to research in topics: Cancer & Comparative genomic hybridization. The author has an hindex of 28, co-authored 98 publications receiving 2594 citations. Previous affiliations of Mario Hermsen include University of Oviedo.
Papers
More filters
Journal ArticleDOI
Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability
Mario Hermsen,Cindy Postma,Jan P. A. Baak,Marjan M. Weiss,A. Rapallo,Andrea Sciutto,Guido M.J.M. Roemen,Jan Willem Arends,Richard A. Williams,Walter Giaretti,Anton F.P.M. de Goeij,Gerrit A. Meijer +11 more
TL;DR: Evidence was found that these chromosomal abnormalities occurred in specific combinations of a few abnormalities rather than as a mere accumulation of events, indicating the existence of multiple independent chromosomal instability pathways of colorectal cancer progression.
Journal ArticleDOI
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma
Jean-Pierre Bayley,Henricus P. M. Kunst,Alberto Cascón,M. L. Sampietro,José Gaal,Esther Korpershoek,Adolfo Hinojar-Gutierrez,Henri J L M Timmers,Lies H. Hoefsloot,Mario Hermsen,Carlos Suárez,A. Karim Hussain,Annette H. J. T. Vriends,Frederik J. Hes,Jeroen C. Jansen,Carli M. J. Tops,Eleonora P M Corssmit,Peter de Knijff,Jacques W.M. Lenders,Cor W. R. J. Cremers,Peter Devilee,Winand N.M. Dinjens,Ronald R. de Krijger,Mercedes Robledo +23 more
TL;DR: It is concluded that SDHAF2 mutation analysis is justified in very young patients with isolated head and neck paraganglioma without mutations in SDHD, SDHC, or SDHB, and in individuals with familial antecedents who are negative for mutations in all other risk genes.
Journal ArticleDOI
Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out
Hartmut P. H. Neumann,Zoran Erlic,Carsten Christof Boedeker,Lisa Rybicki,Mercedes Robledo,Mario Hermsen,Francesca Schiavi,Maurizio Falcioni,Pingling Kwok,C. Bauters,Karen Lampe,Markus Fischer,Emily A Edelman,Diana E. Benn,Bruce G. Robinson,Stefanie Wiegand,Gerd Rasp,Boris A. Stuck,Michael M. Hoffmann,Maren Sullivan,María A. Sevilla,Marjan M. Weiss,Mariola Pęczkowska,Agata Kubaszek,Pascal Pigny,Robyn L. Ward,Diana L. Learoyd,Michael S. Croxson,Dmitry Zabolotny,Svetlana Yaremchuk,Wolfgang Draf,Mihaela Muresan,Robert R. Lorenz,Stephan Knipping,Michael Strohm,Gerhard Dyckhoff,Christoph Matthias,Nicole Reisch,Simon F. Preuss,Dirk Esser,Martin A. Walter,Holger Kaftan,Timo Stöver,Christian Fottner,Harald Gorgulla,Mahdi Malekpour,Masoud Motasaddi Zarandy,Jörg Schipper,Christoph Brase,Alexander Glien,Matthias Kuhnemund,Sven Koscielny,Peter Schwerdtfeger,Matti Välimäki,Witold Szyfter,Ulrich Finckh,Klaus Zerres,Alberto Cascón,Giuseppe Opocher,Gerd Jürgen Ridder,Andrzej Januszewicz,Carlos Suárez,Charis Eng +62 more
TL;DR: Evidence is given that clinical parameters can predict for mutation and help prioritize gene testing to reduce costs in HNP, and such strategy is cost-saving in the practice of genetics-based personalized health care.
Journal ArticleDOI
Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances
TL;DR: Genetic profiling and the development of in vitro cell lines and animal models currently form the basis for future targeted anticancer therapies, and advances in imaging techniques, endoscopic surgical approaches, and radiotherapy are reviewed.
Journal ArticleDOI
High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.
Aaron M. Udager,Delphine Rolland,Jonathan B. McHugh,Bryan L. Betz,Carlos Murga-Zamalloa,Thomas E. Carey,Lawrence J. Marentette,Mario Hermsen,Kathleen E. DuRoss,Megan S. Lim,Kojo S.J. Elenitoba-Johnson,Noah A. Brown +11 more
TL;DR: Identical EGFR genotypes were found in matched pairs of ISP and associated SNSCC, providing the first genetic evidence of a biologic link between these tumors, and rationalize consideration of irreversible EGFR inhibitors in the therapy of these tumors.